TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale
TRxADE Health has announced the filing of its Q1 2024 10-Q report, demonstrating compliance with Nasdaq listing rules and reporting a net income of over $21 million. This significant profit stems from the sale of nearly all assets of its subsidiary, Trxade, Inc., to Micro Merchant Systems, Inc. for $22.66 million. An additional payment of $7.5 million was received in May 2024. The company had previously received a notice of noncompliance from Nasdaq due to a delay in filing the report, but believes it has now rectified the issue.
- Net income of over $21 million reported for Q1 2024.
- Sale of assets to Micro Merchant Systems, Inc. generated $22.66 million in cash.
- Additional payment of $7.5 million received in May 2024.
- Regained compliance with Nasdaq listing rules.
- Received a notice of noncompliance from Nasdaq for delayed filing of Q1 2024 report.
Insights
TRxADE Health's regaining compliance with Nasdaq listing rules and posting a
The sale of assets is a one-time revenue event, not a recurring income stream. Investors should consider this while evaluating the company's long-term financial health. While the immediate rise in net income is positive, the future earnings potential hinges on how effectively the company reinvests the proceeds from the sale or restructures its remaining operations.
Retail investors should also monitor whether TRxADE Health plans to use these funds for expanding its remaining operations or for paying down debt. If the funds are used wisely, this could potentially lead to sustained growth. However, if mismanaged, the long-term financial stability of the company might be at risk.
In terms of compliance, regaining Nasdaq listing rule compliance is positive as it ensures continued listing on the exchange, maintaining liquidity and credibility. This should be viewed favorably, though the noncompliance event itself may signal potential operational inefficiencies that investors should be aware of.
The sale of Trxade, Inc.'s assets has significant implications for TRxADE Health's business strategy. By divesting a major part of its business, the company appears to be narrowing its focus. The market platform for trading pharmaceuticals was a unique niche. Its sale could indicate a strategic pivot, possibly towards a more streamlined or different business model entirely.
This strategic shift could be beneficial if TRxADE Health uses the funds to enter higher growth or more profitable markets. However, there's also risk if the company fails to find as strategically advantageous a market niche as the one they left. Investors should keep an eye on future announcements detailing how the funds from the asset sale are utilized.
From an industry perspective, such a sale might reflect broader trends in the healthcare and pharmaceuticals sector. Companies often divest non-core assets to focus on core competencies, which can sometimes lead to better overall performance. However, it also raises questions about the viability of the business model they exited. Investors should watch for industry movements and competitive responses to gauge the long-term impacts.
TAMPA, FL, June 27, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced today that with the filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), the Company regained compliance with Nasdaq listing rules and posted net income of over
On May 23, 2024, the Company received a standard notice of noncompliance from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q for the first quarter of 2024, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company believes it has now regained compliance with Nasdaq Listing Rule 5250(c)(1) with the filing of its Form 10-Q.
On February 16, 2024, the Company, together with Trxade, Inc., and Micro Merchant Systems, Inc. (“MMS”) entered into an asset purchase agreement (the “APA”) under which MMS agreed to purchase for cash substantially all of the assets of Trxade, Inc. On February 16, 2024, the parties consummated the closing of the transactions contemplated by the APA. Trxade, Inc. operated a web-based market platform designed to enable trading among healthcare buyers and sellers of pharmaceuticals, accessories and services. The purchase price paid at closing was
Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our Company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Investor Contact:
TRxADE Health, Inc.
2420 Brunello Trace
Lutz, Florida 33558
Email: IR@trxade.com
FAQ
What is the net income reported by TRxADE Health for Q1 2024?
Why did TRxADE Health receive a notice of noncompliance from Nasdaq?
Which assets did TRxADE Health sell to achieve positive net income in Q1 2024?
How much did TRxADE Health receive from the sale of Trxade, Inc.'s assets?
What additional payment did TRxADE Health receive in May 2024 related to the sale?
What compliance status did TRxADE Health achieve with Nasdaq after filing its Q1 2024 report?
